(Yicai) Feb. 27 -- Shares of BeOne Medicines fell after the annual earnings of the Chinese biopharmaceutical giant previously known as BeiGene fell short of expectations, despite achieving profitability for the first time.

BeOne [SHA: 688235; HKG: 6160] was trading down 2.4 percent at CNY257.10 (USD37.49) and 1.5 percent at HKD191.50 (USD24.47) in Shanghai and Hong Kong, respectively, as of 2.50 p.m. today. The firm’s New York-listed stock [NASDAQ: ONC] plunged 8.5 percent to USD322.37 yesterday.

Generally accepted accounting principles profit from operations totaled USD447.1 million in the 12 months ended Dec. 31, compared with a GAAP loss of USD568.2 million a year earlier, BeOne said in its 2025 earnings report yesterday. Revenue expanded 40 percent to USD5.3 billion in the period.

The company had earlier predicted to achieve a revenue of USD6.2 billion to USD6.4 billion and a GAAP operating profit of USD700 million to USD800 million last year.

In the fourth quarter, BeOne’s revenue grew 33 percent to USD1.5 billion from the same period last year. Meanwhile, the firm turned a USD79.4 million GAAP loss from operations into a USD185 million GAAP profit.

“These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical development and manufacturing and one of the industry’s deepest and most differentiated pipelines,” said John V. Oyler, co-founder, chairman, and chief executive officer of BeOne.

Product revenue, which accounts for 99 percent of BeOne’s total revenue, totaled USD5.3 billion last year. Global sales of Brukinsa, an oral anticancer medication used to treat some forms of leukemia and lymphoma, surged 49 percent to USD3.9 billion from the year before. Meanwhile, sales of Tevimbra, another oral anticancer drug used to treat various types of esophageal carcinoma, climbed 19 percent to USD737 million.

“Brukinsa has firmly established itself as the global leader in the Bruton’s tyrosine kinase inhibitor class, distinguished by broad regulatory approvals, expanding geographic reach, strong physician adoption, and unmatched long-term efficacy and safety data in chronic lymphocytic leukemia,” Oyler noted. “At the same time, we are securing new indications and expanded reimbursement for Tevimbra across key markets worldwide.

“With our late-stage, foundational hematology assets nearing commercialization and a robust solid tumor portfolio delivering encouraging data, we are well positioned to extend our leadership and drive the next phase of sustainable global growth,” he added.

Editor: Futura Costaglione